Scale club, 10 m.c, U0126 but not U0124 significantly reduced the number of neurons double-labeled with pCREB and pERK1/2 following norepinephrine treatment. Pancreatic and sympathoadrenal activities are vital reactive responses to hypoglycemia (Cryer, 1997). These short-term hypoglycemic counterregulatory components are accompanied by a critical adaptive adrenoglucocorticoid response that ensures long-term metabolic modifications (Watts and Donovan, 2010). Glucocorticoid responses are also sensitive to diabetic hyperinsulinemia RPS6KA6 and hyperglycemia, emphasizing their involvement in diabetes-associated processes (Davis et al., 1994;Fruehwald-Schultes et al., 2001;Chan et al., 2005a,b). Glycemia-related activation of corticotropin-releasing hormone (CRH) neurons in the paraventricular nucleus of the hypothalamus (PVH) and consequent glucocorticoid release rely on signals from hormone- and nutrient-sensing neurons in the hypothalamus and hindbrain. CRH neuroendocrine neurons receive numerous regulatory signals that travel along any of several distinct afferent pathways (Ulrich-Lai and Herman, 2009), including a major set of catecholaminergic inputs from hindbrain regions implicated in glucosensing (Sawchenko and Swanson, 1981;Ritter et al., 2003;Watts and Donovan, 2010). CRH neurons release CRH and/or arginine vasopressin (AVP) into the pituitary portal circulation to trigger adrenocorticotropin (ACTH) and ultimately glucocorticoid secretion in response to these afferent signals. Despite much investigation, how central neural pathways appropriately engage intracellular transduction mechanisms in CRH neurons to initiate the glucocorticoid response to glycemia-related challenges remains unknown. Nor is it clear whether the same pathways and transduction mechanisms are engaged when glucocorticoid activation occurs during other forms of stress. Regulated CRH and AVP release from neuroendocrine terminals requires that depolarization and spike frequency are appropriately coupled to the receptors activated by the afferent pathways encoding the challenges. Additionally, afferent-driven signal transduction must also activate biosynthetic mechanismsparticularly those involving CREBto maintain adequate levels of CRH and AVP in neuroendocrine terminals for sustained ACTH release (Watts, 2005). How these synthetic and release mechanisms couple to neural inputs and to each other in an appropriate stimulus intensity-dependent (i.e., graded) manner is a pivotal part of CRH neuronal function. Clarifying transduction and coupling processes at the cellular and systems level is essential if we are to understand how glycemia-related challenges are decoded by the neuroendocrine hypothalamus. Phosphorylated forms of p44/42 mitogen-activated protein kinases (ERK1/2) increase rapidly in CRH neurons following various systemic challenges; after drug withdrawal; and after central delivery of neurotransmitters, growth factors, and receptor agonists (Daniels et al., 2003;Khan and Watts, 2004;Valjent et al., 2004;Nadjar et al., 2005;Choi GJ-103 free acid et al., 2006;Khan et al., 2007;Nez et al., 2008;Singru et al., 2008;Blume et al., 2009;Manfredsson et al., 2009). We now hypothesize that MEK, which controls phospho(p)-ERK1/2, is a required component of the signaling pathway that links the afferent signals encoding glycemia-related challenges with CRH transcriptional and release responses. Furthermore, we suggest that these MAP kinase cascade components are activated in an appropriate and intensity-dependent manner by glycemic and other challenges. We also test the necessity of ascending catecholaminergic projections to engage these signaling processes during two widely used glycemic challenges [intravenous insulin and GJ-103 free acid 2-deoxy-d-glucose (2-DG)], and then ask whether norepinephrine-driven CREB phosphorylation and neuronal firing rates are each MEK-dependent. We test these hypotheses in three convergent sets ofin vivoandex vivoexperiments. == Materials and Methods == == == == Animals == Adult male Sprague Dawley rats (315 g body weight at surgery) from Harlan were housed in climate-controlled conditions (2022C; 12 h light/12 h dark; lights on 6:00 A.M.) with unrestricted food and water access. GJ-103 free acid Local institute animal care and use committees approved all experimental procedures. == In vivoprocedures == == Catecholaminergic denervation of the PVH. == Bilateral PVH injections (42 ng/200 nl) of a cell-lethal conjugate of saporin and a mouse monoclonal dopamine–hydroxylase (DBH) antibody (DSAP; Advanced Targeting Systems) or equimolar concentrations of saporin conjugated to nonspecific mouse IgG (MSAP) were delivered 2 weeks before any vascular injection, as previously described (Ritter et al., 2001,2003). == Catheters and injections. == One week after DSAP/MSAP injections, rats were fitted with jugular catheters, as previously described (Khan and Watts, 2004;Khan et al., 2007). These allowed for vascular injections to be performed with minimal stress to the subjects and for rapid delivery of anesthetic, ensuring short durations between animal knockdown and perfusion. == Glycemic and multimodal challenges. == At least 14 d after MSAP or DSAP injections, groups of rats were challenged with intravenous.